Ryan P. Cantwell Chater

Ryan P. Cantwell Chater

Auto-generated profile, based on publicly available information

Ryan P. Cantwell Chater

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in Journal of Neurochemistry
Verified
Journal Article
Open access
RCRyan Cantwell Chater
Ryan Cantwell Chater
AQAda S. Quinn
Ada S. Quinn
KWKatie Wilson
Katie Wilson
ZFZachary J. Frangos
Zachary J. Frangos
PSPatrick Sutton
Patrick Sutton
Robert VandenbergRobert Vandenberg
Robert Vandenberg
Glycine Transporter 2 (GlyT2) inhibitors have shown considerable potential as analgesics for the treatment of neuropathic pain but also display considerable side effects. One potential source of side effects is irreversible inhibition. In this study, we have characterized the mechanism of ORG25543 inhibition of GlyT2 by first considering three potential ligand binding sites on GlyT2—the substrate site, the vestibule allosteric site and the lipid allosteric site. The three sites were tested using a combination of molecular dynamics simulations and analysis of the inhibition of glycine transport of a series point mutated GlyT2 using electrophysiological methods. We demonstrate that the lipid allosteric site on GlyT2 is the most likely binding site for ORG25543. We also demonstrate that cholesterol derived from the cell membrane can form specific interactions with inhibitor‐bound transporters to form an allosteric network of regulatory sites. These observations will guide the future design of GlyT2 inhibitors with the objective of minimising on‐target side effects and improving the therapeutic window for the treatment of patients suffering from neuropathic pain. image

28 August 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CCChristopher L. Cioffi
Christopher L. Cioffi
ILIrina Lotsaris
Irina Lotsaris
RCRyan P. Cantwell Chater
Ryan P. Cantwell Chater
TPTanmay K. Pati
Tanmay K. Pati
KSKrishna Suleria
Krishna Suleria
RVRobert J. Vandenberg
Robert J. Vandenberg

23 January 2023 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
ZFZachary J Frangos
Zachary J Frangos
KWKatie Wilson
Katie Wilson
HAHeather M Aitken
Heather M Aitken
RCRyan Cantwell Chater
Ryan Cantwell Chater
Robert VandenbergRobert Vandenberg
Robert Vandenberg
MOMegan L. O'Mara
Megan L. O'Mara
Membrane cholesterol binds to and modulates the function of various SLC6 neurotransmitter transporters, including stabilizing the outward-facing conformation of the dopamine and serotonin transporters. Here, we investigate how cholesterol binds to GlyT2 (SLC6A5), modulates glycine transport rate, and influences bioactive lipid inhibition of GlyT2. Bioactive lipid inhibitors are analgesics that bind to an allosteric site accessible from the extracellular solution when GlyT2 adopts an outward-facing conformation. Using molecular dynamics simulations, mutagenesis, and cholesterol depletion experiments, we show that bioactive lipid inhibition of glycine transport is modulated by the recruitment of membrane cholesterol to a binding site formed by transmembrane helices 1, 5, and 7. Recruitment involves cholesterol flipping from its membrane orientation, and insertion of the 3′ hydroxyl group into the cholesterol binding cavity, close to the allosteric site. The synergy between cholesterol and allosteric inhibitors provides a novel mechanism of inhibition and a potential avenue for the development of potent GlyT2 inhibitors as alternative therapeutics for the treatment of neuropathic pain and therapeutics that target other SLC6 transporters.

16 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRyan P. Cantwell Chater
Ryan P. Cantwell Chater
JPJulian Peiser-Oliver
Julian Peiser-Oliver
TPTanmay K. Pati
Tanmay K. Pati
AQAda S. Quinn
Ada S. Quinn
ILIrina Lotsaris
Irina Lotsaris
ASAzadeh Shahsavar
Azadeh Shahsavar
Chronic neuropathic pain, caused by nerve damage or disease, is increasing in prevalence, but current treatments are ineffective and over-reliant on opioids. The neuronal glycine transporter, GlyT2, regulates inhibitory glycinergic neurotransmission and represents a promising target for new analgesics. However, most GlyT2 inhibitors cause significant side effects, in part due to irreversible inhibition at analgesic doses. Here we develop a reversible inhibitor of GlyT2, RPI-GLYT2-82, and identify its binding site by determining cryo-EM structures of human GlyT2. We capture three fundamental conformational states of GlyT2 in the substrate-free state, and bound to either glycine, RPI-GLYT2-82 or the pseudo-irreversible inhibitor ORG25543. We demonstrate that RPI-GLYT2-82 dissociates from GlyT2 faster than ORG25543, providing analgesia in mouse neuropathic pain models without on-target side-effects or addiction liability. Our data provide a mechanistic understanding of allosteric inhibition of glycine transport, enabling structure-based design of non-opioid analgesics.

24 April 2025 in bioRxiv
Verified
Preprint
Open access
RCRyan P. Cantwell Chater
Ryan P. Cantwell Chater
JPJulian Peiser-Oliver
Julian Peiser-Oliver
TPTanmay K. Pati
Tanmay K. Pati
AQAda S. Quinn
Ada S. Quinn
ILIrina Lotsaris
Irina Lotsaris
ASAzadeh Shahsavar
Azadeh Shahsavar
Chronic neuropathic pain, caused by nerve damage or disease, is increasing in prevalence, but current treatments are ineffective and over-reliant on opioids. The neuronal glycine transporter, GlyT2, regulates inhibitory glycinergic neurotransmission and represents a promising target for new analgesics. However, most GlyT2 inhibitors cause significant side effects, in part due to irreversible inhibition at analgesic doses. Here we develop a reversible inhibitor of GlyT2, RPI-GLYT2-82, and identify its binding site by determining cryo-EM structures of human GlyT2. We capture three fundamental conformational states of GlyT2 in the substrate-free state, and bound to either glycine, RPI-GLYT2-82 or the pseudo-irreversible inhibitor ORG25543. We demonstrate that RPI-GLYT2-82 dissociates from GlyT2 faster than ORG25543, providing analgesia in mouse neuropathic pain models without on-target side-effects or addiction liability. Our data provide a mechanistic understanding of allosteric inhibition of glycine transport, enabling structure-based design of non-opioid analgesics.

15 April 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CCChristopher L. Cioffi
Christopher L. Cioffi
TPTanmay K. Pati
Tanmay K. Pati
ILIrina Lotsaris
Irina Lotsaris
SJSrinivasan Jayakumar
Srinivasan Jayakumar
JPJulian Peiser-Oliver
Julian Peiser-Oliver
Robert VandenbergRobert Vandenberg
Robert Vandenberg